SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending with intense anticipation for its Phase 3 REGAL trial results, as the extended timeline is widely seen by the community as a positive indicator of 'curative outcomes' and a potential buyout. Investors are largely dismissing bearish sentiment and focusing on increasing institutional interest and the transformative potential of the company's dual cancer platforms.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending following multiple analyst upgrades with significantly higher price targets and anticipation around management's comments on stabilizing the BetterHelp segment and addressing debt. The community is actively debating its extreme undervaluation compared to sector peers and its strong free cash flow, fueling speculation of a potential short squeeze amid optimism for its global virtual care platform and AI initiatives.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending after reporting a significant Q4 earnings beat driven by strong MIPLYFFA sales, which is signaling a shift to profitability and sparking community discussions about its re-rating potential and a possible short squeeze.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Crane Harbor Acquisition Corp.

CHAC is trending as its merger target, Xanadu Quantum Technologies, announced a significant collaboration with AMD to accelerate quantum computing for aerospace and engineering, fueling community excitement over its real-world applications and strong client roster. Investors are actively watching the anticipated merger, with many adding the pure-play photonic quantum computing leader to their watchlists and discussing its potential compared to past successful SPACs in the burgeoning sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending due to President Trump's public statements declaring the Iran war "very complete" and his subsequent news conference, which is sparking immediate market conversation around oil prices and stability; however, community perspectives are divided on the actual resolution and its broader implications.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is trending following a mixed earnings report that saw an EPS beat but a revenue miss and cautious forward guidance, sparking debate among investors. Bulls are highlighting strengthened cash flow and the company's underlying real estate value, while bears point to soft sales and the challenging retail landscape, all amplified by significant short interest.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is actively discussed after announcing a merger with U.S. defense prime contractor Mistral Inc., a move many view as a transformative step providing direct access to significant Department of Defense programs and expanding its role in the autonomous defense market. While bulls are enthusiastic about this strategic positioning, community dialogue also reflects concerns regarding potential share dilution from the all-stock deal and its immediate impact on stock performance ahead of upcoming earnings.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is actively discussed amid conflicting reports on the Middle East conflict; bulls eye a "Trump pump" after claims of the war being "pretty much done," while bears highlight rising oil prices and Iranian denials, fueling concerns of manipulation and a market reversal.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending due to a bullish analyst upgrade and the upcoming R2 vehicle reveal, fueling community debate on its path to profitability and scalability, especially as rising oil prices present both opportunities and challenges for the broader EV sector.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending following its announcement of a proposed convertible senior notes offering, which has sparked community concern over potential dilution and questions regarding management's capital strategy despite significant existing cash reserves. Many are expressing frustration, especially in contrast to positive developments from its partner, Vertex Pharmaceuticals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celcuity CEO Details Gedatolisib NDA, July PDUFA and Launch Plans at TD Cowen Conference

Celcuity (NASDAQ:CELC) CEO and co-founder Brian Sullivan outlined the company's clinical programs, regulatory progress, and commercial launch preparations for gedatolisib during a fireside chat at TD...

Vanguard Group Inc. Raises Stock Position in Celcuity, Inc. $CELC

Vanguard Group Inc. grew its stake in shares of Celcuity, Inc. (NASDAQ:CELC - Free Report) by 23.5% in the third quarter, according to the company in its most recent 13F filing with the Securities...

TD Asset Management Inc Invests $3.60 Million in Celcuity, Inc. $CELC

TD Asset Management Inc purchased a new stake in Celcuity, Inc. (NASDAQ:CELC - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities...

Artisan Partners Limited Partnership Boosts Stock Holdings in Celcuity, Inc. $CELC

Artisan Partners Limited Partnership lifted its position in Celcuity, Inc. (NASDAQ:CELC - Free Report) by 45.9% in the 3rd quarter, according to the company in its most recent 13F filing with the...

Patient Square Capital LP Acquires Shares of 100,000 Celcuity, Inc. $CELC

Patient Square Capital LP acquired a new stake in Celcuity, Inc. (NASDAQ:CELC - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position

Key PointsPerceptive Advisors purchased 203,881 Celcuity shares in the fourth quarter; the estimated trade value was $16.76 million based on average fourth-quarter pricing...

Celcuity, Inc. (NASDAQ:CELC) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the stock, Marketbeat.com reports...

Has Celcuity (CELC) Outpaced Other Medical Stocks This Year?

Here is how Celcuity, Inc. (CELC) and Day One Biopharmaceuticals, Inc. (DAWN) have performed compared to their sector so far this year.

Soleus Adds a Significant Number of Celcuity Shares

Key PointsSoleus increased its Celcuity stake by 629,398 shares...

Celcuity CEO Sets July 17 PDUFA for Gedatolisib, Teases VIKTORIA-1 Mutant Data at Conference

Celcuity (NASDAQ:CELC) CEO Brian Sullivan outlined the company's expected regulatory timeline and commercial preparations for gedatolisib during an appearance at the Guggenheim Healthcare Conference...

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Current Price	$113.45
Prev Close	$115.00
Open	$114.00
Dividend Yield	0.00%
50-Day Moving Average	$107.54
Beta	0.99
Avg. Volume	644,283.74
PE Ratio	-30.90

52-Week High	$120.32
52-Week Low	$7.58
Market Capitalization	$5.25B
EPS (Annual)	-$2.83
Price to Book	41.97
Revenue Per Employee	$0.00

CELC
Celcuity Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CELC News

CELCCelcuity Inc